Posts Tagged ‘BiondVax Pharmaceuticals’
Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8 Million Underwritten Public Offering of BiondVax Pharmaceuticals Ltd.
Press Release – New York, NY – December 21, 2022 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as sole book running manager in the $8 Million underwritten public offering of BiondVax Pharmaceuticals, a biotechnology company which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products. The offering consisted of 1,600,000…
Read MoreSichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd.
Sichenzia Ross Ference LLP Represents Aegis Capital in $12.1 Million Follow-On Offering of BiondVax Pharmaceuticals Ltd. American Depositary Shares
Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar & Co., LLC in $10 Million Public Offering of American Depository Shares of BiondVax Pharmaceuticals Ltd. (Israel)
